On Monday July 12th, Nephron hosted Ross Margulies of Foley Hoag. Topics of discussion included:

• The status of 340B under the Biden administration, including the threat to fine drug makers for curtailing distribution of discounted drugs to contract pharmacies, the role, if any of alternative dispute resolution to resolve the issue, and what might be next from the administration.
• An update on the many lawsuits by drug makers, hospitals and other entities concerning the contract pharmacy issue.
• Forecasting the most likely legal, legislative, and regulatory outcome.